You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

Xpert Xpress SARS-CoV-2 Test

News Releases

Cepheid Schedules 2010 Third Quarter Financial Results Announcement and Webcast

SUNNYVALE, Calif., Oct. 7 /PRNewswire-FirstCall/ -- Cepheid today announced that it will report financial results for its third quarter ended September 30, 2010, on Thursday, October 21, 2010, after the close of the market.

The company will host a management presentation at 2 p.m. Pacific Time on Thursday, October 21, 2010, to discuss the results.  To access the live webcast, please visit Cepheid's website at www.cepheid.com/investors at least 15 minutes before the scheduled start time to download any necessary audio or plug-in software.  A replay of the webcast will be available shortly following the call and will remain available for at least 90 days.

Interested participants and investors may also listen to the live teleconference call by dialing (866) 788-0538 (domestic) or (857) 350 1676 (international), and entering participant code 51795047.  A replay will be available for seven days beginning at 4 p.m. Pacific Time.  Access numbers for this replay are (888) 286-8010 (domestic) and (617) 801-6888 (international), with passcode 72854495.

About Cepheid

Based in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is an on-demand molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial and biothreat markets.  The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures.  The company's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges.  Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market.  See http://www.cepheid.com for more information.

CONTACTS:


For Media Inquiries:

For Investor Inquiries:

Jared Tipton

Jacquie Ross

Cepheid Corporate Communications

Cepheid Investor Relations

Tel: (408) 400 8377

Tel: (408) 400 8329

jared.tipton@cepheid.com

investor.relations@cepheid.com



SOURCE Cepheid

For further information: media, Jared Tipton, +1-408-400-8377, jared.tipton@cepheid.com, or investors, Jacquie Ross, +1-408-400-8329, investor.relations@cepheid.com, both of Cepheid
Back to Top